Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AFIBNYSE:ISRNASDAQ:LUCDNASDAQ:NVNO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFIBAcutus Medical$0.17+0.1%$0.19$0.16▼$1.09$5.19M0.191.96 million shs85,168 shsISRIsoray$0.37$0.19▼$0.45$54.57M1.48290,697 shs145,000 shsLUCDLucid Diagnostics$0.79-1.1%$1.10$0.76▼$1.85$38.13M1.63139,473 shs73,920 shsNVNOenVVeno Medical$4.81+0.6%$5.53$2.51▼$6.97$64.07M1.17117,896 shs17,494 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFIBAcutus Medical+5.52%-3.85%-9.99%-2.77%-75.78%ISRIsoray0.00%0.00%0.00%0.00%0.00%LUCDLucid Diagnostics-0.26%-6.91%-25.93%-44.83%-50.00%NVNOenVVeno Medical-0.42%-5.72%-16.14%+19.50%+4.60%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAFIBAcutus MedicalN/AN/AN/AN/AN/AN/AN/AN/AISRIsorayN/AN/AN/AN/AN/AN/AN/AN/ALUCDLucid Diagnostics1.8834 of 5 stars3.53.00.00.02.61.70.0NVNOenVVeno Medical0.1898 of 5 stars0.02.00.00.01.91.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFIBAcutus MedicalN/AN/AN/AN/AISRIsorayN/AN/AN/AN/ALUCDLucid Diagnostics3.00Buy$2.75247.88% UpsideNVNOenVVeno MedicalN/AN/AN/AN/ACurrent Analyst RatingsLatest AFIB, ISR, LUCD, and NVNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.503/27/2024LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$3.80 ➝ $3.003/27/2024LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.50(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFIBAcutus Medical$7.16M0.73N/AN/A($0.03) per share-5.82ISRIsoray$10.80M0.00N/AN/A$0.43 per share0.00LUCDLucid Diagnostics$2.43M15.69N/AN/A($0.47) per share-1.68NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFIBAcutus Medical-$81.66M-$1.24N/A∞N/A-166.79%-35.31%-13.43%5/9/2024 (Estimated)ISRIsoray-$7.27M-$0.07N/AN/AN/A-115.91%-17.12%-16.15%N/ALUCDLucid Diagnostics-$52.67M-$1.27N/A∞N/A-2,169.07%-901.79%-121.11%5/20/2024 (Estimated)NVNOenVVeno Medical-$23.52M-$1.92N/AN/AN/AN/A-70.17%-64.68%5/6/2024 (Estimated)Latest AFIB, ISR, LUCD, and NVNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023LUCDLucid DiagnosticsN/A-$0.26-$0.26-$0.26N/A$1.04 million 2/29/2024Q4 2023NVNOenVVeno MedicalN/A-$0.32-$0.32-$0.32N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFIBAcutus MedicalN/AN/AN/AN/AN/AISRIsorayN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFIBAcutus Medical1.102.442.22ISRIsorayN/A14.3813.99LUCDLucid DiagnosticsN/A0.750.74NVNOenVVeno MedicalN/A34.2234.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFIBAcutus Medical56.91%ISRIsoray11.32%LUCDLucid Diagnostics74.01%NVNOenVVeno Medical34.71%Insider OwnershipCompanyInsider OwnershipAFIBAcutus Medical3.50%ISRIsoray2.42%LUCDLucid Diagnostics4.80%NVNOenVVeno Medical17.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAFIBAcutus Medical23029.72 million28.68 millionOptionableISRIsorayN/A142.11 million138.67 millionNot OptionableLUCDLucid Diagnostics7048.24 million45.93 millionNo DataNVNOenVVeno Medical1913.32 million11.05 millionOptionableAFIB, ISR, LUCD, and NVNO HeadlinesSourceHeadlineNew Topline Efficacy Data from the enVVeno Medical…pharmiweb.com - April 16 at 1:05 PMNew Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024finance.yahoo.com - April 16 at 1:05 PMenVVeno Medical hires new CCO to guide transitionuk.investing.com - April 11 at 9:42 AMenVVeno Medical Corporation: enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officerfinanznachrichten.de - April 10 at 4:14 AMenVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officerfinance.yahoo.com - April 9 at 12:21 PMenVVeno Medical Corporation (NASDAQ:NVNO) CTO Hamed Alavi Sells 8,334 Sharesinsidertrades.com - March 16 at 10:58 AMNVNO Apr 2024 10.000 callfinance.yahoo.com - March 16 at 2:23 AMenVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunityfinance.yahoo.com - March 15 at 11:16 AMPositive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meetingfinance.yahoo.com - March 6 at 5:49 PMCompanies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growthfinance.yahoo.com - March 3 at 11:28 AMenVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 8:20 PMRecap: enVVeno Medical Q4 Earningsbenzinga.com - February 29 at 8:20 PMenVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 29 at 8:20 PMTopline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024finance.yahoo.com - February 20 at 10:08 AMenVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitabilityfinance.yahoo.com - January 6 at 9:49 AMNVNO Jan 2024 5.000 callca.finance.yahoo.com - December 29 at 4:00 PMenVVeno Medical Corporation: enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposiumfinanznachrichten.de - December 14 at 12:07 PMenVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposiumfinance.yahoo.com - December 14 at 12:07 PMenVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposiumfinance.yahoo.com - November 16 at 9:45 AMenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - October 26 at 8:13 PMenVVeno Medical files to sell 14.71M shares for holdersmsn.com - October 26 at 8:13 PMenVVeno Medical reports Q3 resultsmsn.com - October 26 at 3:10 PMenVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - October 26 at 8:22 AMenVVeno Medical to Participate at the Virtual Investor Ask the CEO Conferencefinance.yahoo.com - October 12 at 1:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideBuckle Up or Bail Out? The Self-Driving Taxi Market's Risky RideApril 16, 2024 9:45 AMView Buckle Up or Bail Out? The Self-Driving Taxi Market's Risky RideAll Headlines Company DescriptionsAcutus MedicalNASDAQ:AFIBAcutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.IsorayNYSE:ISRIsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.Lucid DiagnosticsNASDAQ:LUCDLucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.enVVeno MedicalNASDAQ:NVNOenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.